分化型甲状腺癌绝经前女性的性功能与抑郁症状:横断面研究
该横断面研究纳入110例接受稳定TSH抑制治疗的分化型甲状腺癌(DTC)绝经前女性(按TSH水平分三组)和40例健康对照,评估性功能障碍(FSFI)和抑郁症状(BDI-II)。DTC组性功能障碍和抑郁症状发生率均高于对照(53.6% vs. 10%;65.5% vs. 15%),TSH抑制越强损伤越重,且TSH抑制和更高BDI-II评分与性功能障碍风险独立相关。
要点
- DTC绝经前女性性功能障碍和抑郁症状发生率显著高于健康对照。
- TSH抑制程度越强,性功能和抑郁症状损伤越明显。
- TSH抑制和更高BDI-II评分与性功能障碍风险独立相关。
核心结论
- DTC绝经前女性性功能障碍和抑郁症状比健康对照更常见。
- 在DTC女性中,TSH抑制越强,性功能和抑郁症状恶化越明显。
- 长期管理DTC女性需纳入心理和性健康评估。
研究设计与样本
- 横断面研究,纳入110例接受稳定TSH抑制治疗的DTC绝经前女性,按TSH水平(<0.1、0.1-0.5、0.5-2.5 mIU/mL)分三组,另设40例健康对照。
- 使用女性性功能指数(FSFI)评估性功能,贝克抑郁量表-II(BDI-II)评估抑郁症状。
- 检测甲状腺功能、甲状腺抗体和性激素,并进行相关和logistic回归分析。
主要发现
- DTC组性功能障碍发生率为53.6%,健康对照为10%;抑郁症状发生率为65.5%,对照为15%。
- BDI-II评分升高与FSFI总分及欲望、满意度、疼痛子领域评分呈负相关。
- TSH水平与FSFI评分呈正相关,游离甲状腺素和游离三碘甲状腺原氨酸与满意度和润滑呈负相关。
- 甲状腺球蛋白抗体水平升高与更高抑郁评分相关。
- logistic回归显示TSH抑制和更高BDI-II评分与性功能障碍风险独立相关。
临床怎么用
- 对DTC绝经前女性应常规评估抑郁症状和性功能障碍。
- 制定TSH抑制方案时需权衡心理和性健康影响。
局限性
- 横断面设计无法推断因果关系。
- 样本量有限,仅纳入绝经前女性,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy, disproportionately affecting women. Despite excellent survival outcomes, DTC treatment, particularly long-term thyrotropin (TSH) suppression therapy, has been associated with differences in psychological well-being and sexual function. Although the association between thyroid dysfunction and female sexual dysfunction (FSD) is well-established, limited data exist regarding FSD in premenopausal women with DTC. OBJECTIVE: To investigate the presence and severity of depressive symptoms and FSD in premenopausal women with DTC and examine their association with thyroid hormone levels and thyroid autoimmunity. METHODS: This cross-sectional study included 110 premenopausal women with DTC on stable TSH suppression therapy, stratified into three groups by TSH level (<0.1, 0.1-0.5, and 0.5-2.5 mIU/mL), and 40 healthy controls. Sexual function and depressive symptoms were assessed using the Female Sexual Function Index (FSFI) and Beck Depression Inventory-II (BDI-II), respectively. Thyroid function tests, thyroid antibodies, and sex hormones were evaluated. Correlation and logistic regression analyses were performed. RESULTS: Women with DTC showed higher rates of sexual dysfunction and depressive symptoms than controls (FSD 53.6% vs. 10%; depressive symptoms 65.5% vs. 15%), with the greatest impairment under stronger TSH suppression. Increased BDI-II scores were inversely correlated with FSFI total and subdomain scores (desire, satisfaction, pain). TSH levels were positively associated with FSFI scores, while free thyroxine and free triiodothyronine showed inverse correlations with satisfaction and lubrication. Elevated thyroglobulin antibody levels were associated with higher depression scores. Multivariable models were adjusted for age. Covariates included body mass index, risk of recurrence, disease duration, TSH, free thyroxine, free triiodothyronine, thyroglobulin antibody, total testosterone, prolactin, and BDI-II. Logistic regression analysis showed that suppressed TSH and higher BDI-II scores were independently associated with higher odds of FSD. CONCLUSIONS: Sexual dysfunction and depressive symptoms were more frequent in women with DTC than in healthy controls; moreover, among women with DTC, the greatest deterioration was seen in those receiving stronger TSH suppression. These findings highlighted the need for comprehensive care that includes psychological and sexual health assessment in the long-term management of women with DTC.
引用
- Demir AN, Sahin S, Gulhan D, et al. Sexual Function and Depressive Symptoms in Premenopausal Women with Differentiated Thyroid Cancer: A Cross-Sectional Study. Thyroid. 2026. PMID: 41761664. doi:10.1177/10507256261427804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。